Skip to main content
Erschienen in:

22.10.2018 | review

Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse

verfasst von: Ali Amin Asnafi, Niloofar Farshchi, Abbas Khosravi, Neda Ketabchi, Masumeh Maleki Behzad, Saeid Shahrabi, Ph.D

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Summary

Background

Leukemia is one of the most important hematological malignancies. Despite progress in leukemia therapy, recurrence is still one of the main reasons for treatment failure. Recently, gene polymorphisms have been the focus of attention as important factors in the recurrence of leukemia.

Methods

Relevant literature was identified by an electronic database search (1996–2018) of English-language literature using the terms “polymorphism”, “leukemia”, “prognosis”, “lymphoma”, and “relapse.”

Results

Polymorphisms of genes involved in cell cycle, apoptosis, immune system, and drug metabolism enzymes have been associated with progression of hematological malignancies. These genetic changes can be associated with relapse and unfavorable clinical outcomes through potential impact on leukemic cells survival.

Conclusion

Considering the fact that gene polymorphisms could significantly affect pathophysiology of hematological malignancies, these genetic changes may be considered as potential prognostic biomarkers and therapeutic agents in these disorders.
Literatur
1.
Zurück zum Zitat Saki N, Abroun S, Hagh MF, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J. 2011;13(3):131.PubMedPubMedCentral Saki N, Abroun S, Hagh MF, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J. 2011;13(3):131.PubMedPubMedCentral
2.
Zurück zum Zitat Han F, Tan Y, Cui W, Dong L, Li W. Novel insights into etiologies of leukemia: a HuGE review and meta-analysis of CYP1A1 polymorphisms and leukemia risk. Am J Epidemiol. 2013;178(4):493–507.CrossRefPubMed Han F, Tan Y, Cui W, Dong L, Li W. Novel insights into etiologies of leukemia: a HuGE review and meta-analysis of CYP1A1 polymorphisms and leukemia risk. Am J Epidemiol. 2013;178(4):493–507.CrossRefPubMed
3.
Zurück zum Zitat Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann J, Groeneveld T, Körner G, Seeger K. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B‑cell precursor acute lymphoblastic leukemia. Leukemia. 2013;27(2):295.CrossRefPubMed Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, Engelmann J, Groeneveld T, Körner G, Seeger K. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B‑cell precursor acute lymphoblastic leukemia. Leukemia. 2013;27(2):295.CrossRefPubMed
4.
Zurück zum Zitat Esmatabadi MJD, Bakhshinejad B, Motlagh FM, Babashah S, Sadeghizadeh M. Therapeutic resistance and cancer recurrence mechanisms: unfolding the story of tumour coming back. J Biosci. 2016;41(3):497–506.CrossRefPubMed Esmatabadi MJD, Bakhshinejad B, Motlagh FM, Babashah S, Sadeghizadeh M. Therapeutic resistance and cancer recurrence mechanisms: unfolding the story of tumour coming back. J Biosci. 2016;41(3):497–506.CrossRefPubMed
5.
Zurück zum Zitat Zhu Y, Foroni L, McQuaker I, Papaioannou M, Haynes A, Russell H. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer. 1999;79(7–8):1151.CrossRefPubMedPubMedCentral Zhu Y, Foroni L, McQuaker I, Papaioannou M, Haynes A, Russell H. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer. 1999;79(7–8):1151.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Cristóbal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Jose’Calasanz M, Odero MD. Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2011;97(4):543–50.CrossRefPubMed Cristóbal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Jose’Calasanz M, Odero MD. Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2011;97(4):543–50.CrossRefPubMed
8.
Zurück zum Zitat Kirschner-Schwabe R, Lottaz C, Tödling J, Rhein P, Karawajew L, Eckert C, von Stackelberg A, Ungethüm U, Kostka D, Kulozik AE. Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia. Clin Cancer Res. 2006;12(15):4553–61.CrossRefPubMed Kirschner-Schwabe R, Lottaz C, Tödling J, Rhein P, Karawajew L, Eckert C, von Stackelberg A, Ungethüm U, Kostka D, Kulozik AE. Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia. Clin Cancer Res. 2006;12(15):4553–61.CrossRefPubMed
9.
Zurück zum Zitat Karathanasis NV, Choumerianou DM, Kalmanti M. Gene polymorphisms in childhood ALL. Pediatr Blood Cancer. 2009;52(3):318–23.CrossRefPubMed Karathanasis NV, Choumerianou DM, Kalmanti M. Gene polymorphisms in childhood ALL. Pediatr Blood Cancer. 2009;52(3):318–23.CrossRefPubMed
10.
Zurück zum Zitat Valibeigi B, Amirghofran Z, Golmoghaddam H, Hajihosseini R, Kamazani FM. Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis. Pathol Oncol Res. 2014;20(2):367–74.CrossRefPubMed Valibeigi B, Amirghofran Z, Golmoghaddam H, Hajihosseini R, Kamazani FM. Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis. Pathol Oncol Res. 2014;20(2):367–74.CrossRefPubMed
11.
Zurück zum Zitat Babor F, Manser AR, Fischer JC, Scherenschlich N, Enczmann J, Chazara O, Moffett A, Borkhardt A, Meisel R, Uhrberg M. The KIR ligand C2 is associated with increased susceptibility to childhood acute lymphoblastic leukemia and confers an elevated risk for late relapse. Blood. 2014;124(14):2248–51.CrossRefPubMed Babor F, Manser AR, Fischer JC, Scherenschlich N, Enczmann J, Chazara O, Moffett A, Borkhardt A, Meisel R, Uhrberg M. The KIR ligand C2 is associated with increased susceptibility to childhood acute lymphoblastic leukemia and confers an elevated risk for late relapse. Blood. 2014;124(14):2248–51.CrossRefPubMed
12.
Zurück zum Zitat Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S‑transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B‑cell precursor acute lymphoblastic leukemia: a case-control study. Blood. 2000;95(4):1222–8.PubMed Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S‑transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B‑cell precursor acute lymphoblastic leukemia: a case-control study. Blood. 2000;95(4):1222–8.PubMed
13.
Zurück zum Zitat Hajizamani S, Shahjahani M, Shahrabi S, Saki N. MicroRNAs as prognostic biomarker and relapse indicator in leukemia. Clin Transl Oncol. 2017;19(8):951–60.CrossRefPubMed Hajizamani S, Shahjahani M, Shahrabi S, Saki N. MicroRNAs as prognostic biomarker and relapse indicator in leukemia. Clin Transl Oncol. 2017;19(8):951–60.CrossRefPubMed
14.
Zurück zum Zitat Hessels AC, Rutgers A, Sanders JSF, Stegeman CA. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study. PLoS ONE. 2018;13(4):e195524.CrossRefPubMedPubMedCentral Hessels AC, Rutgers A, Sanders JSF, Stegeman CA. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study. PLoS ONE. 2018;13(4):e195524.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Fujita K, Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007;8(6):554–62.CrossRefPubMed Fujita K, Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007;8(6):554–62.CrossRefPubMed
16.
Zurück zum Zitat Vujkovic M, Kershenbaum A, Wray L, McWilliams T, Cannon S, Devidas M, Stork L, Aplenc R. Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG–1952. Leuk Res Rep. 2015;4(2):47–50.PubMedPubMedCentral Vujkovic M, Kershenbaum A, Wray L, McWilliams T, Cannon S, Devidas M, Stork L, Aplenc R. Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG–1952. Leuk Res Rep. 2015;4(2):47–50.PubMedPubMedCentral
17.
Zurück zum Zitat Evans WE. Pharmacogenetics of thiopurine S‑methyltransferase and thiopurine therapy. Ther Drug Monit. 2004;26(2):186–91.CrossRefPubMed Evans WE. Pharmacogenetics of thiopurine S‑methyltransferase and thiopurine therapy. Ther Drug Monit. 2004;26(2):186–91.CrossRefPubMed
18.
Zurück zum Zitat Fredriksen Å, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat. 2007;28(9):856–65.CrossRefPubMed Fredriksen Å, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat. 2007;28(9):856–65.CrossRefPubMed
19.
Zurück zum Zitat O’Leary VB, Mills JL, Pangilinan F, Kirke PN, Cox C, Conley M, Weiler A, Peng K, Shane B, Scott JM. Analysis of methionine synthase reductase polymorphisms for neural tube defects risk association. Mol Genet Metab. 2005;85(3):220–7.CrossRefPubMed O’Leary VB, Mills JL, Pangilinan F, Kirke PN, Cox C, Conley M, Weiler A, Peng K, Shane B, Scott JM. Analysis of methionine synthase reductase polymorphisms for neural tube defects risk association. Mol Genet Metab. 2005;85(3):220–7.CrossRefPubMed
20.
Zurück zum Zitat Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res. 1988;202(2):343–61.CrossRefPubMed Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res. 1988;202(2):343–61.CrossRefPubMed
21.
Zurück zum Zitat Krajinovic M, Labuda D, Sinnett D. Glutathione S‑transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenet Genomics. 2002;12(8):655–8.CrossRef Krajinovic M, Labuda D, Sinnett D. Glutathione S‑transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenet Genomics. 2002;12(8):655–8.CrossRef
22.
Zurück zum Zitat Reilly R, McNulty H, Pentieva K, Strain J, Ward M. MTHFR 677TT genotype and disease risk: is there a modulating role for B‑vitamins? Proc Nutr Soc. 2014;73(1):47–56.CrossRefPubMed Reilly R, McNulty H, Pentieva K, Strain J, Ward M. MTHFR 677TT genotype and disease risk: is there a modulating role for B‑vitamins? Proc Nutr Soc. 2014;73(1):47–56.CrossRefPubMed
23.
Zurück zum Zitat Sepe DM, McWilliams T, Chen J, Kershenbaum A, Zhao H, La M, Devidas M, Lange B, Rebbeck TR, Aplenc R. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer. 2012;58(5):695–700.CrossRefPubMed Sepe DM, McWilliams T, Chen J, Kershenbaum A, Zhao H, La M, Devidas M, Lange B, Rebbeck TR, Aplenc R. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer. 2012;58(5):695–700.CrossRefPubMed
24.
Zurück zum Zitat Hanson NQ, Aras Ö, Yang F, Tsai MY. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem. 2001;47(4):661–6.PubMed Hanson NQ, Aras Ö, Yang F, Tsai MY. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem. 2001;47(4):661–6.PubMed
25.
Zurück zum Zitat Niedzielska E, Węcławek-Tompol J, Matkowska-Kocjan A, Chybicka A. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate. Adv Clin Exp Med. 2013;22(4):579–84.PubMed Niedzielska E, Węcławek-Tompol J, Matkowska-Kocjan A, Chybicka A. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate. Adv Clin Exp Med. 2013;22(4):579–84.PubMed
26.
Zurück zum Zitat Candelaria M, Ojeda J, Gutiérrez-Hernández O, Taja-Chayeb L, Vidal-Millán S, Dueñas-González A. G80A single nucleotide polymorphism in reduced folate carrier-1 gene in a mexican population and its impact on survival in patients with acute lymphoblastic leukemia. Rev Invest Clin. 2016;68(3):154–62.PubMed Candelaria M, Ojeda J, Gutiérrez-Hernández O, Taja-Chayeb L, Vidal-Millán S, Dueñas-González A. G80A single nucleotide polymorphism in reduced folate carrier-1 gene in a mexican population and its impact on survival in patients with acute lymphoblastic leukemia. Rev Invest Clin. 2016;68(3):154–62.PubMed
27.
Zurück zum Zitat Liu S‑G, Gao C, Zhang R‑D, Jiao Y, Cui L, Li W‑J, Chen Z‑P, Wu M‑Y, Zheng H‑Y, Zhao X‑X. FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B‑cell precursor acute lymphoblastic leukemia. Cancer Cell Int. 2013;13(1):107.CrossRefPubMedPubMedCentral Liu S‑G, Gao C, Zhang R‑D, Jiao Y, Cui L, Li W‑J, Chen Z‑P, Wu M‑Y, Zheng H‑Y, Zhao X‑X. FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B‑cell precursor acute lymphoblastic leukemia. Cancer Cell Int. 2013;13(1):107.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Gómez-Gómez Y, Organista-Nava J, Rangel-Rodriguez CA, Illades-Aguiar B, Moreno-Godínez ME, Alarcón-Romero LDC, Leyva-Vázquez MA. Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia. Oncol Lett. 2014;8(2):731–5.CrossRefPubMedPubMedCentral Gómez-Gómez Y, Organista-Nava J, Rangel-Rodriguez CA, Illades-Aguiar B, Moreno-Godínez ME, Alarcón-Romero LDC, Leyva-Vázquez MA. Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia. Oncol Lett. 2014;8(2):731–5.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst. 1996;88(8):496–509.CrossRefPubMed Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst. 1996;88(8):496–509.CrossRefPubMed
30.
Zurück zum Zitat Hengstler J, Arand M, Herrero M, Oesch F. Polymorphisms of N‑acetyltransferases, glutathione S‑transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. In: Genes and environment in cancer. Heidelberg, Berlin, New York: Springer; 1998. pp. 47–85.CrossRef Hengstler J, Arand M, Herrero M, Oesch F. Polymorphisms of N‑acetyltransferases, glutathione S‑transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. In: Genes and environment in cancer. Heidelberg, Berlin, New York: Springer; 1998. pp. 47–85.CrossRef
31.
Zurück zum Zitat Iyer L, Ratain M. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998;34(10):1493–9.CrossRefPubMed Iyer L, Ratain M. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998;34(10):1493–9.CrossRefPubMed
32.
Zurück zum Zitat Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 2016;76(1):7–9.CrossRefPubMed Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 2016;76(1):7–9.CrossRefPubMed
33.
Zurück zum Zitat Leonardi DB, Abbate M, Riccheri MC, Nuñez M, Alfonso G, Gueron G, De Siervi A, Vazquez E, Cotignola J. Improving risk stratification of patients with childhood acute lymphoblastic leukemia: glutathione-S-transferases polymorphisms are associated with increased risk of relapse. Oncotarget. 2017;8(1):110.CrossRefPubMed Leonardi DB, Abbate M, Riccheri MC, Nuñez M, Alfonso G, Gueron G, De Siervi A, Vazquez E, Cotignola J. Improving risk stratification of patients with childhood acute lymphoblastic leukemia: glutathione-S-transferases polymorphisms are associated with increased risk of relapse. Oncotarget. 2017;8(1):110.CrossRefPubMed
34.
Zurück zum Zitat Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia. 2002;16(8):1437.CrossRefPubMed Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia. 2002;16(8):1437.CrossRefPubMed
35.
Zurück zum Zitat de Deus DMV, de Souza PRE, Muniz MTC. High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia. Mol Biol Rep. 2013;40(2):1609–13.CrossRefPubMed de Deus DMV, de Souza PRE, Muniz MTC. High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia. Mol Biol Rep. 2013;40(2):1609–13.CrossRefPubMed
36.
Zurück zum Zitat Lu Y, Kham S, Ariffin H, Oei A, Lin H, Tan A, Quah T, Yeoh A. Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia. Br J Cancer. 2014;110(6):1673.CrossRefPubMedPubMedCentral Lu Y, Kham S, Ariffin H, Oei A, Lin H, Tan A, Quah T, Yeoh A. Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia. Br J Cancer. 2014;110(6):1673.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Gagné V, Rousseau J, Labuda M, Sharif-Askari B, Brukner I, Laverdiere C, Ceppi F, Sallan SE, Silverman LB, Neuberg D. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res. 2013;19(18):5240–9.CrossRefPubMedPubMedCentral Gagné V, Rousseau J, Labuda M, Sharif-Askari B, Brukner I, Laverdiere C, Ceppi F, Sallan SE, Silverman LB, Neuberg D. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res. 2013;19(18):5240–9.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Eisfeld A‑K, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. Proc Natl Acad Sci USA. 2012;109(17):6668–73.CrossRefPubMedPubMedCentral Eisfeld A‑K, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. Proc Natl Acad Sci USA. 2012;109(17):6668–73.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Nadimi M, Rahgozar S, Moafi A, Tavassoli M, Tanha HM. Evaluation of rs62527607 [GT] single nucleotide polymorphism located in BAALC gene in children with acute leukemia using mismatch PCR-RFLP. Cancer Genet. 2016;209(7):348–53.CrossRefPubMed Nadimi M, Rahgozar S, Moafi A, Tavassoli M, Tanha HM. Evaluation of rs62527607 [GT] single nucleotide polymorphism located in BAALC gene in children with acute leukemia using mismatch PCR-RFLP. Cancer Genet. 2016;209(7):348–53.CrossRefPubMed
40.
Zurück zum Zitat Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470–80.CrossRefPubMedPubMedCentral Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470–80.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Davidsson J, Paulsson K, Lindgren D, Lilljebjörn H, Chaplin T, Forestier E, Andersen M, Nordgren A, Rosenquist R, Fioretos T. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia. 2010;24(5):924.CrossRefPubMed Davidsson J, Paulsson K, Lindgren D, Lilljebjörn H, Chaplin T, Forestier E, Andersen M, Nordgren A, Rosenquist R, Fioretos T. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia. 2010;24(5):924.CrossRefPubMed
42.
Zurück zum Zitat Mosaad YM, Elashery R, Darwish A, Sharaf Eldein OA, Barakat T, Marouf S, Abou El-Khier NT, Youssef LF, Fawzy IM. GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact. Leuk Lymphoma. 2017;58(3):689–98.CrossRefPubMed Mosaad YM, Elashery R, Darwish A, Sharaf Eldein OA, Barakat T, Marouf S, Abou El-Khier NT, Youssef LF, Fawzy IM. GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact. Leuk Lymphoma. 2017;58(3):689–98.CrossRefPubMed
43.
Zurück zum Zitat Shahrabi S, Behzad MM, Jaseb K, Saki N. Thrombocytopenia in leukemia: pathogenesis and prognosis. Histol Histopathol. 2018;33(9):895–908.PubMed Shahrabi S, Behzad MM, Jaseb K, Saki N. Thrombocytopenia in leukemia: pathogenesis and prognosis. Histol Histopathol. 2018;33(9):895–908.PubMed
44.
Zurück zum Zitat Long J, Fang S, Dai Q, Liu X, Zhu W, Wang S. The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis. Oncotarget. 2016;7(22):32079.CrossRefPubMedPubMedCentral Long J, Fang S, Dai Q, Liu X, Zhu W, Wang S. The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis. Oncotarget. 2016;7(22):32079.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Megías-Vericat J, Rojas L, Herrero M, Bosó V, Montesinos P, Moscardó F, Poveda J, Sanz MÁ, Aliño S. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15(2):109.CrossRefPubMed Megías-Vericat J, Rojas L, Herrero M, Bosó V, Montesinos P, Moscardó F, Poveda J, Sanz MÁ, Aliño S. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15(2):109.CrossRefPubMed
46.
Zurück zum Zitat Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, Kawai H, Sato A, Miyamoto M, Toyosaki M. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol. 2015;101(6):543–53.CrossRefPubMed Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, Kawai H, Sato A, Miyamoto M, Toyosaki M. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol. 2015;101(6):543–53.CrossRefPubMed
47.
Zurück zum Zitat Wan H, Zhu J, Chen F, Xiao F, Huang H, Han X, Zhong L, Zhong H, Xu L, Ni B. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(1):90.CrossRefPubMedPubMedCentral Wan H, Zhu J, Chen F, Xiao F, Huang H, Han X, Zhong L, Zhong H, Xu L, Ni B. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(1):90.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Zhang D‑Y, Yuan X‑Q, Yan H, Cao S, Zhang W, Li X‑L, Zeng H, Chen X‑P. Association between DCK 35708 T> C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients. Pharmacogenomics. 2016;17(14):1519–31.CrossRefPubMed Zhang D‑Y, Yuan X‑Q, Yan H, Cao S, Zhang W, Li X‑L, Zeng H, Chen X‑P. Association between DCK 35708 T> C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients. Pharmacogenomics. 2016;17(14):1519–31.CrossRefPubMed
49.
Zurück zum Zitat Cheong HS, Koh Y, Ahn K‑S, Lee C, Shin HD, Yoon S‑S. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia. Pharmacogenet Genomics. 2014;24(9):436–41.CrossRefPubMed Cheong HS, Koh Y, Ahn K‑S, Lee C, Shin HD, Yoon S‑S. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia. Pharmacogenet Genomics. 2014;24(9):436–41.CrossRefPubMed
50.
Zurück zum Zitat Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G, Schaich M. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955–62.PubMed Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G, Schaich M. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955–62.PubMed
51.
Zurück zum Zitat Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH, Matalka II, Haddadin WJ, Mahasneh IO, Aldaher AN. Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s lymphoma. J Exp Clin Cancer Res. 2011;30(1):68.CrossRefPubMedPubMedCentral Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH, Matalka II, Haddadin WJ, Mahasneh IO, Aldaher AN. Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s lymphoma. J Exp Clin Cancer Res. 2011;30(1):68.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with Gemtuzumab-Ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620–7.CrossRefPubMedPubMedCentral Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with Gemtuzumab-Ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620–7.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Kim M, Kim J, Kim JR, Han E, Park J, Lim J, Kim Y, Han K, Kim H‑J, Min W‑S. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1. Mol Biol Rep. 2015;42(2):451–6.CrossRefPubMed Kim M, Kim J, Kim JR, Han E, Park J, Lim J, Kim Y, Han K, Kim H‑J, Min W‑S. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1. Mol Biol Rep. 2015;42(2):451–6.CrossRefPubMed
54.
Zurück zum Zitat Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children’s Oncology Group and SWOG. Blood. 2011;118(17):4561–6.CrossRefPubMedPubMedCentral Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children’s Oncology Group and SWOG. Blood. 2011;118(17):4561–6.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647.CrossRefPubMed Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647.CrossRefPubMed
56.
Zurück zum Zitat Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Meka P, Annamaneni S, Digumarthi R, Sinha S. Influence of BCL2-938C> A and BAX-248G> A promoter polymorphisms in the development of AML: case-control study from South India. Tumor Biol. 2015;36(10):7967–76.CrossRef Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Meka P, Annamaneni S, Digumarthi R, Sinha S. Influence of BCL2-938C> A and BAX-248G> A promoter polymorphisms in the development of AML: case-control study from South India. Tumor Biol. 2015;36(10):7967–76.CrossRef
57.
Zurück zum Zitat Niavarani A, Horswell S, Sadri R, Bonnet D. The Wilms tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia. Ann Hematol. 2016;95(2):179–90.CrossRefPubMed Niavarani A, Horswell S, Sadri R, Bonnet D. The Wilms tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia. Ann Hematol. 2016;95(2):179–90.CrossRefPubMed
58.
Zurück zum Zitat Damm F, Heuser M, Morgan M, Yun H, Großhennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2009;28(4):578–85.CrossRefPubMed Damm F, Heuser M, Morgan M, Yun H, Großhennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2009;28(4):578–85.CrossRefPubMed
59.
Zurück zum Zitat Dolz S, García P, Llop M, Fuster Ó, Luna I, Ibáñez M, Gómez I, López M, Such E, Cervera J. Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia. Leuk Lymphoma. 2016;57(2):429–35.CrossRefPubMed Dolz S, García P, Llop M, Fuster Ó, Luna I, Ibáñez M, Gómez I, López M, Such E, Cervera J. Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia. Leuk Lymphoma. 2016;57(2):429–35.CrossRefPubMed
60.
Zurück zum Zitat Nückel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, Jöckel K‑H, Dührsen U, Siffert W. Association of a novel regulatory polymorphism (−938C> A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290–7.CrossRefPubMed Nückel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, Jöckel K‑H, Dührsen U, Siffert W. Association of a novel regulatory polymorphism (−938C> A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290–7.CrossRefPubMed
61.
Zurück zum Zitat Shahjahani M, Mohammadiasl J, Noroozi F, Seghatoleslami M, Shahrabi S, Saba F, Saki N. Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. Cell Oncol. 2015;38(2):93–109.CrossRef Shahjahani M, Mohammadiasl J, Noroozi F, Seghatoleslami M, Shahrabi S, Saba F, Saki N. Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. Cell Oncol. 2015;38(2):93–109.CrossRef
62.
Zurück zum Zitat Van Bockstaele F, Pede V, Janssens A, Callewaert F, Offner F, Verhasselt B, Philippé J. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem. 2007;53(2):204–12.CrossRefPubMed Van Bockstaele F, Pede V, Janssens A, Callewaert F, Offner F, Verhasselt B, Philippé J. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem. 2007;53(2):204–12.CrossRefPubMed
63.
Zurück zum Zitat Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C. High expression of lipoprotein lipase in poor risk B‑cell chronic lymphocytic leukemia. Leukemia. 2005;19(7):1216.CrossRefPubMed Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C. High expression of lipoprotein lipase in poor risk B‑cell chronic lymphocytic leukemia. Leukemia. 2005;19(7):1216.CrossRefPubMed
64.
Zurück zum Zitat Rombout A, Stamatopoulos B, Lagneaux L, Lust S, Offner F, Naessens E, Vanderstraeten H, Verhasselt B, Philippé J. Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. PLoS ONE. 2015;10(3):e121526.CrossRefPubMedPubMedCentral Rombout A, Stamatopoulos B, Lagneaux L, Lust S, Offner F, Naessens E, Vanderstraeten H, Verhasselt B, Philippé J. Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. PLoS ONE. 2015;10(3):e121526.CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Staff PO. Correction: lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. PLoS ONE. 2015;10(6):e131029.CrossRef Staff PO. Correction: lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. PLoS ONE. 2015;10(6):e131029.CrossRef
66.
Zurück zum Zitat Nückel H, Frey U, Aral N, Dürig J, Dührsen U, Siffert W. The CC genotype of the C825T polymorphism of the G protein β3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44(10):1739–43.CrossRefPubMed Nückel H, Frey U, Aral N, Dürig J, Dührsen U, Siffert W. The CC genotype of the C825T polymorphism of the G protein β3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44(10):1739–43.CrossRefPubMed
67.
Zurück zum Zitat Penna G, Allegra A, Alonci A, Aguennouz M, Garufi A, Cannavo A, Gerace D, Alibrandi A, Musolino C. MDR-1 polymorphisms (G2677T and C3435T) in B‑chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol. 2011;28(4):1549–54.CrossRefPubMed Penna G, Allegra A, Alonci A, Aguennouz M, Garufi A, Cannavo A, Gerace D, Alibrandi A, Musolino C. MDR-1 polymorphisms (G2677T and C3435T) in B‑chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol. 2011;28(4):1549–54.CrossRefPubMed
68.
Zurück zum Zitat Lordelo G, Miranda-Vilela A, Akimoto A, Alves P, Hiragi C, Nonino A, Daldegan M, Klautau-Guimarães M, Grisolia C. Association between methylene tetrahydrofolate reductase and glutathione S‑transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Genet Mol Res. 2012;11(2):1013–26.CrossRefPubMed Lordelo G, Miranda-Vilela A, Akimoto A, Alves P, Hiragi C, Nonino A, Daldegan M, Klautau-Guimarães M, Grisolia C. Association between methylene tetrahydrofolate reductase and glutathione S‑transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Genet Mol Res. 2012;11(2):1013–26.CrossRefPubMed
69.
Zurück zum Zitat Kassogue Y, Quachouh M, Dehbi H, Quessar A, Benchekroun S, Nadifi S. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Med Oncol. 2014;31(1):782.CrossRefPubMed Kassogue Y, Quachouh M, Dehbi H, Quessar A, Benchekroun S, Nadifi S. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Med Oncol. 2014;31(1):782.CrossRefPubMed
70.
Zurück zum Zitat Kim DHD, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15(14):4750–8.CrossRefPubMed Kim DHD, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15(14):4750–8.CrossRefPubMed
71.
Zurück zum Zitat Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, Ie Coutre P, Nagler A. OCT 1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol. 2014;92(4):283–8.CrossRefPubMed Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, Ie Coutre P, Nagler A. OCT 1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol. 2014;92(4):283–8.CrossRefPubMed
72.
Zurück zum Zitat Pehlivan M, Sahin HH, Pehlivan S, Ozdilli K, Kaynar L, Oguz FS, Sever T, Yilmaz M, Eser B, Ogret YD. Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia. Genet Test Mol Biomarkers. 2014;18(6):403–9.CrossRefPubMedPubMedCentral Pehlivan M, Sahin HH, Pehlivan S, Ozdilli K, Kaynar L, Oguz FS, Sever T, Yilmaz M, Eser B, Ogret YD. Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia. Genet Test Mol Biomarkers. 2014;18(6):403–9.CrossRefPubMedPubMedCentral
73.
Zurück zum Zitat Amirzargar A, Bagheri M, Ghavamzadeh A, Alimoghadam K, Khosravi F, Rezaei N, Moheydin M, Ansaripour B, Moradi B, Nikbin B. Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia. Int J Immunogenet. 2005;32(3):167–71.CrossRefPubMed Amirzargar A, Bagheri M, Ghavamzadeh A, Alimoghadam K, Khosravi F, Rezaei N, Moheydin M, Ansaripour B, Moradi B, Nikbin B. Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia. Int J Immunogenet. 2005;32(3):167–71.CrossRefPubMed
74.
Zurück zum Zitat Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood. 2009;114(5):1046–52.CrossRefPubMedPubMedCentral Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood. 2009;114(5):1046–52.CrossRefPubMedPubMedCentral
75.
Zurück zum Zitat Azizidoost S, Bavarsad MS, Bavarsad MS, Shahrabi S, Jaseb K, Rahim F, Shahjahani M, Saba F, Ghorbani M, Saki N. The role of notch signaling in bone marrow niche. Hematology. 2015;20(2):93–103.CrossRefPubMed Azizidoost S, Bavarsad MS, Bavarsad MS, Shahrabi S, Jaseb K, Rahim F, Shahjahani M, Saba F, Ghorbani M, Saki N. The role of notch signaling in bone marrow niche. Hematology. 2015;20(2):93–103.CrossRefPubMed
76.
Zurück zum Zitat Varga G, Mikala G, Andrikovics H, Koszarska M, Balassa K, Ádám E, Kozma A, Tordai A, Masszi T. NFKB 1–94ins/del ATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. Br J Haematol. 2015;168(5):679–88.CrossRefPubMed Varga G, Mikala G, Andrikovics H, Koszarska M, Balassa K, Ádám E, Kozma A, Tordai A, Masszi T. NFKB 1–94ins/del ATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. Br J Haematol. 2015;168(5):679–88.CrossRefPubMed
77.
Zurück zum Zitat Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H. Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002;100(6):2263–5.PubMed Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H. Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002;100(6):2263–5.PubMed
78.
Zurück zum Zitat Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 2012;131(5):E636–E42.CrossRefPubMed Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 2012;131(5):E636–E42.CrossRefPubMed
79.
Zurück zum Zitat Ortega MM, Honma HN, Zambon L, Lorand-Metze I, Costa FF, De Souza CA, Lima CS. GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Ann Hematol. 2007;86(11):815–9.CrossRefPubMed Ortega MM, Honma HN, Zambon L, Lorand-Metze I, Costa FF, De Souza CA, Lima CS. GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Ann Hematol. 2007;86(11):815–9.CrossRefPubMed
80.
Zurück zum Zitat Hattori Y, Ikeda Y, Suzuki Y, Ichikawa D, Matsushita M. Codon 72 polymorphism of TP 53 gene is a novel prognostic marker for therapy in multiple myeloma. Br J Haematol. 2014;165(5):728–31.CrossRefPubMed Hattori Y, Ikeda Y, Suzuki Y, Ichikawa D, Matsushita M. Codon 72 polymorphism of TP 53 gene is a novel prognostic marker for therapy in multiple myeloma. Br J Haematol. 2014;165(5):728–31.CrossRefPubMed
81.
Zurück zum Zitat Fabre C, Mimura N, Bobb K, Kong S‑Y, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J. Dual inhibition of canonical and non-canonical NF-κB pathways demonstrates significant anti-tumor activities in multiple myeloma. Clin Cancer Res. 2012;18(17):4669–81.CrossRefPubMedPubMedCentral Fabre C, Mimura N, Bobb K, Kong S‑Y, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J. Dual inhibition of canonical and non-canonical NF-κB pathways demonstrates significant anti-tumor activities in multiple myeloma. Clin Cancer Res. 2012;18(17):4669–81.CrossRefPubMedPubMedCentral
82.
Zurück zum Zitat Du J, Huo J, Shi J, Yuan Z, Zhang C, Fu W, Jiang H, Yi Q, Hou J. Polymorphisms of NF-κB family genes are associated with development of multiple myeloma and treatment outcome in patients undergoing bortezomib-based regimens. Haematologica. 2011;96(5):729–37.CrossRefPubMedPubMedCentral Du J, Huo J, Shi J, Yuan Z, Zhang C, Fu W, Jiang H, Yi Q, Hou J. Polymorphisms of NF-κB family genes are associated with development of multiple myeloma and treatment outcome in patients undergoing bortezomib-based regimens. Haematologica. 2011;96(5):729–37.CrossRefPubMedPubMedCentral
83.
Zurück zum Zitat Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-hodgkin lymphoma. Lancet. 2017;390(10091):298–310.CrossRefPubMed Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-hodgkin lymphoma. Lancet. 2017;390(10091):298–310.CrossRefPubMed
84.
Zurück zum Zitat Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol. 2010;85(1):51–6.PubMedPubMedCentral Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol. 2010;85(1):51–6.PubMedPubMedCentral
86.
Zurück zum Zitat D’Angelo V, Ramaglia M, Iannotta A, Francese M, Pota E, Affinita MC, Pecoraro G, Indolfi C, Di Martino M, Di Pinto D. Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Leuk Lymphoma. 2013;54(12):2639–44.CrossRefPubMed D’Angelo V, Ramaglia M, Iannotta A, Francese M, Pota E, Affinita MC, Pecoraro G, Indolfi C, Di Martino M, Di Pinto D. Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Leuk Lymphoma. 2013;54(12):2639–44.CrossRefPubMed
87.
Zurück zum Zitat Ni Y, Yin G, Xiao Z, Fan L, Wang L, Wu Y, Wu H, Qian S, Xu W, Li J. MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients. Tumor Biol. 2016;37(1):1237–44.CrossRef Ni Y, Yin G, Xiao Z, Fan L, Wang L, Wu Y, Wu H, Qian S, Xu W, Li J. MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients. Tumor Biol. 2016;37(1):1237–44.CrossRef
88.
Zurück zum Zitat Nedoszytko B, Olszewska B, Roszkiewicz J, Glen J, Zabłotna M, Ługowska-Umer H, Nowicki R, Sokołowska-Wojdyło M. The role of polymorphism of interleukin-2,-10,-13 and TNF-α genes in cutaneous T‑cell lymphoma pathogenesis. Postepy Dermatol Alergol. 2016;33(6):429.CrossRefPubMedPubMedCentral Nedoszytko B, Olszewska B, Roszkiewicz J, Glen J, Zabłotna M, Ługowska-Umer H, Nowicki R, Sokołowska-Wojdyło M. The role of polymorphism of interleukin-2,-10,-13 and TNF-α genes in cutaneous T‑cell lymphoma pathogenesis. Postepy Dermatol Alergol. 2016;33(6):429.CrossRefPubMedPubMedCentral
89.
Zurück zum Zitat Gao S, Zhu G, Lin Y, Fan X, Qian P, Zhu J, Yu Y. Tumor necrosis factor-308 polymorphism with the risk and prognosis of non-Hodgkin lymphomas: a meta-analysis study. Onco Targets Ther. 2016;9:1657.CrossRefPubMedPubMedCentral Gao S, Zhu G, Lin Y, Fan X, Qian P, Zhu J, Yu Y. Tumor necrosis factor-308 polymorphism with the risk and prognosis of non-Hodgkin lymphomas: a meta-analysis study. Onco Targets Ther. 2016;9:1657.CrossRefPubMedPubMedCentral
90.
Zurück zum Zitat Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG. Genetic variation in tumor necrosis factor and the nuclear factor-κB canonical pathway and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3161–9.CrossRefPubMedPubMedCentral Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG. Genetic variation in tumor necrosis factor and the nuclear factor-κB canonical pathway and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3161–9.CrossRefPubMedPubMedCentral
91.
Zurück zum Zitat Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv. 2012;6(1):102–14.CrossRefPubMed Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv. 2012;6(1):102–14.CrossRefPubMed
92.
Zurück zum Zitat Zhang W, Wang X, Li J, Duan M, Zhou D. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B‑cell lymphoma. Chin Med J. 2010;123(2):198–202.PubMed Zhang W, Wang X, Li J, Duan M, Zhou D. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B‑cell lymphoma. Chin Med J. 2010;123(2):198–202.PubMed
93.
Zurück zum Zitat Burkhardt B, Yavuz D, Zimmermann M, Schieferstein J, Kabickova E, Attarbaschi A, Lisfeld J, Reiter A, Makarova O, Worch J. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Ann Hematol. 2016;95(9):1503–12.CrossRefPubMed Burkhardt B, Yavuz D, Zimmermann M, Schieferstein J, Kabickova E, Attarbaschi A, Lisfeld J, Reiter A, Makarova O, Worch J. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Ann Hematol. 2016;95(9):1503–12.CrossRefPubMed
94.
Zurück zum Zitat Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism. Int Immunol. 2012;24(8):477–83.CrossRefPubMed Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism. Int Immunol. 2012;24(8):477–83.CrossRefPubMed
Metadaten
Titel
Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse
verfasst von
Ali Amin Asnafi
Niloofar Farshchi
Abbas Khosravi
Neda Ketabchi
Masumeh Maleki Behzad
Saeid Shahrabi, Ph.D
Publikationsdatum
22.10.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0446-5

Weitere Artikel der Ausgabe 4/2018

memo - Magazine of European Medical Oncology 4/2018 Zur Ausgabe